Published in Int J Cardiol on July 18, 2006
Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia (2009) 2.03
Diversity of metabolic syndrome criteria in association with cardiovascular diseases--a family medicine-based investigation. Med Sci Monit (2013) 1.01
Prevalence of the metabolic syndrome in Pudong New Area of Shanghai using three proposed definitions among Chinese adults. BMC Public Health (2010) 1.00
Prevalence of cardiovascular risk factors and the metabolic syndrome in middle-aged men and women in Gothenburg, Sweden. BMC Public Health (2008) 0.95
Does prevalence of the metabolic syndrome in women with coronary artery disease differ by the ATP III and IDF criteria? J Womens Health (Larchmt) (2008) 0.92
Prevalence of metabolic syndrome in elderly and agreement among four diagnostic criteria. Arq Bras Cardiol (2014) 0.88
Implementation of guidelines for the management of arterial hypertension. The impulsion study. Open Cardiovasc Med J (2009) 0.85
Prevalence of metabolic syndrome components among the elderly using three different definitions: a cohort study in Finland. Scand J Prim Health Care (2012) 0.84
Variations in prevalent cardiovascular disease and future risk by metabolic syndrome classification in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Am Heart J (2010) 0.84
A comparison of predictability of cardiovascular events between each metabolic component in patients with metabolic syndrome based on the revised National Cholesterol Education Program criteria. Yonsei Med J (2011) 0.84
Metabolic syndrome in peritoneal dialysis patients. NDT Plus (2008) 0.82
Microencapsulated conjugated linoleic acid associated with hypocaloric diet reduces body fat in sedentary women with metabolic syndrome. Vasc Health Risk Manag (2012) 0.79
Establishment of Health Clinics as Mass Screening and Referral Systems for Chronic Non-communicable Diseases in Primary Health Care. Int J Prev Med (2012) 0.78
Circulatory syndrome: an evolution of the metabolic syndrome concept! Curr Cardiol Rev (2012) 0.78
The COSEHC™ Global Vascular Risk Management quality improvement program: first follow-up report. Vasc Health Risk Manag (2013) 0.77
Comparison of four definitions of the metabolic syndrome and odds of ischemic heart disease in the Lithuanian urban population. Int J Public Health (2011) 0.75
Hyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography. PLoS One (2017) 0.75
Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA (2012) 9.37
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab (2009) 2.50
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J (2004) 2.09
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
The hyponatremic patient: a systematic approach to laboratory diagnosis. CMAJ (2002) 1.67
Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf (2008) 1.58
The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol (2013) 1.53
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin (2011) 1.53
Atorvastatin: safety and tolerability. Expert Opin Drug Saf (2010) 1.47
Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose. Metab Syndr Relat Disord (2012) 1.44
Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int (2006) 1.42
Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. Thyroid (2003) 1.40
Unexplained hypertransaminasaemia: clue to diagnosis of Addison's disease. Eur J Gastroenterol Hepatol (2002) 1.40
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin (2011) 1.39
Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin's lymphoma. Ann Hematol (2004) 1.39
Multiple actions of high-density lipoprotein. Curr Opin Cardiol (2008) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
CORONA, statins, and heart failure: who lost the crown? Angiology (2008) 1.38
Is angioedema a class adverse effect of the angiotensin-converting enzyme inhibitors? Ann Allergy Asthma Immunol (2007) 1.38
Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) (2009) 1.29
Gender-related and age-related urinalysis of healthy subjects by NMR-based metabonomics. NMR Biomed (2008) 1.25
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs (2010) 1.18
An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther (2008) 1.16
The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol (2010) 1.14
Novel roles of vitamin D in disease: what is new in 2011? Eur J Intern Med (2011) 1.14
Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto's thyroiditis. Thyroid (2007) 1.12
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Hyperuricemia as a risk factor for cardiovascular disease. Expert Rev Cardiovasc Ther (2014) 1.11
Metformin and cancer. Eur J Pharmacol (2013) 1.11
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol (2007) 1.09
Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Diabetologia (2015) 1.08
Pleiotropic effects of statins--clinical evidence. Curr Pharm Des (2009) 1.08
Cold temperature and cardiovascular mortality. Circ J (2013) 1.07
Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". Dig Liver Dis (2012) 1.06
Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention. Circ J (2013) 1.06
Metabolic syndrome in clinical practice. Cardiol J (2014) 1.06
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf (2008) 1.05
Evaluation of methods for the measurement of low-density lipoprotein cholesterol. J Cardiovasc Pharmacol Ther (2005) 1.05
Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol (2010) 1.03
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des (2010) 1.02
Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci (2013) 1.01
Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin (2010) 1.01
Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets (2010) 1.01
Dyslipidemia in patients with thyroid disorders. Hormones (Athens) (2006) 1.01
Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des (2011) 1.01
Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium (2008) 0.99
Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke (2005) 0.99
Dyslipidemia as a risk factor for ischemic stroke. Curr Top Med Chem (2009) 0.99
Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol (2006) 0.99
Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin (2004) 0.97
Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. Eur J Heart Fail (2002) 0.97
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci (2011) 0.96
Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids (2008) 0.96
Correlation of Achilles tendon thickness evaluated by ultrasonography with carotid intima-media thickness in patients with familial hypercholesterolemia. Atherosclerosis (2006) 0.96
Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk? Curr Vasc Pharmacol (2010) 0.95
Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol (2012) 0.95
Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr Drug Targets (2009) 0.95
Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int J Cardiol (2005) 0.95
Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol (2010) 0.94
Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? Curr Opin Cardiol (2010) 0.94
Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment? Arch Med Sci (2011) 0.94
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology (2011) 0.94
Evaluation of alternative calculation methods for determining low-density lipoprotein cholesterol in hemodialysis patients. Clin Biochem (2004) 0.94
Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis (2008) 0.94
Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol (2011) 0.94
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother (2007) 0.93
Hyperuricaemia: more than just a cause of gout? J Cardiovasc Med (Hagerstown) (2013) 0.92
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol (2013) 0.92
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther (2007) 0.92
Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. Nephrol Dial Transplant (2006) 0.92
Statin pleiotropy against renal injury. J Cardiometab Syndr (2009) 0.92
Carbon dioxide balneotherapy and cardiovascular disease. Int J Biometeorol (2010) 0.92
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther (2006) 0.91
Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? Expert Opin Pharmacother (2007) 0.91
A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism (2012) 0.91